CardiaMetrics is proud to be featured in Présences Grenoble, highlighting our journey and our ambition to transform heart failure care through innovative monitoring technologies.

Read the full article on Présences Grenoble.

A Growing Medtech Presence in Grenoble

The article highlights CardiaMetrics’ presence in the Grenoble ecosystem, a region recognized for its strong deeptech and healthcare innovation environment. Alongside our roots in Normandy, our footprint in Grenoble reinforces our ability to combine scientific excellence, engineering, and clinical partnerships.

This dual anchoring reflects our ambition to build a high-impact medtech company at the intersection of research, technology, and patient care.

Addressing a Major Unmet Medical Need

CardiaMetrics is developing a home-based remote monitoring solution for patients with heart failure, a chronic disease affecting millions worldwide.

As emphasized in the article, heart failure management remains a major challenge due to the difficulty of detecting early signs of decompensation. Our approach aims to provide continuous, reliable, and actionable physiological insights, enabling clinicians to intervene earlier and improve patient outcomes.

Innovation at the Core: Data, Sensors, and AI

The Présences Grenoble feature underlines the technological foundations of our solution, combining:

• Advanced physiological sensing
• Data science and machine learning
• A strong clinical validation strategy

By leveraging these pillars, CardiaMetrics is working to deliver scalable and clinically relevant monitoring, bridging the gap between traditional telemonitoring and more invasive solutions.

Building Momentum

This media recognition reflects the progress CardiaMetrics has made over the past months — from team growth and clinical development to increased visibility within the innovation ecosystem.

We are grateful for the continued support of our partners, investors, and the broader medtech community as we move forward.

We are proud to announce that CardiaMetrics has successfully completed its second fundraising round, securing €1.7 million in new investment to fuel the next phase of our development. This milestone reflects growing confidence in our vision to transform the management of heart failure through advanced remote monitoring technologies — and signals a strong step forward in our journey since our first successful €300K seed round in 2024.

Building on Our Early Progress

A little over a year ago, we shared the exciting news of our first funding round, in which we raised €300,000 from private investors and leading cardiologists who recognized the unique value of our solution for bridging the gap between non-invasive telemonitoring approaches and implantable pressure sensors.

That funding enabled us to lay strong foundations — accelerating key strategic hires and preparing our first clinical studies in collaboration with the Caen University Hospital (CHU de Caen) to validate clinical safety and kick off our AI strategy.

Today, with €2M raised, we are ready to accelerate even further.

What This Funding Enables

This latest round will support several high-impact strategic pillars:

We have also established a Strategic Advisory Committee, bringing together experienced clinicians and industry leaders to guide our clinical strategy and reinforce our market positioning moving forward.

Strengthening Our Vision and Market Opportunity

Since our first fundraising announcement, CardiaMetrics has continued to assert its position in the heart failure telemonitoring landscape by combining cutting-edge sensing technologies, AI capabilities, and a deep clinical partnership model (10 clinical centers will onboard in our next clinical study). This new funding reflects investor confidence in our mission to provide clinically relevant, home-based telemetry that meaningfully impacts patient care.

With heart failure affecting millions worldwide and health systems seeking solutions that both improve outcomes and optimize costs, CardiaMetrics is uniquely positioned to help shift care paradigms from reactive to proactive, preventive strategies.

What’s Next

We remain deeply committed to our clinical milestones, regulatory pathway, and expansion goals — with ambitious plans to scale our solution across Europe and USA.

Stay tuned as we continue to publish updates on our clinical progress, scientific collaborations, and technology development throughout 2026 and beyond.

CardiaMetrics is proud to announce that our first scientific results will be presented at Technology and Heart Failure Therapeutics (THT) in Boston (Home Page | THT 2026), one of the world’s leading conferences dedicated to breakthrough technologies in heart failure care.

Our abstract, entitled:

“Cutaneous device and machine learning could estimate pulmonary capillary wedge pressure in patients with heart failure”

has been selected for presentation during:

HF Insight – First-in-Man / Early Feasibility Studies Abstracts Session III
📅 Wednesday, March 4
🕘 9:15 AM – 10:21 AM (ET)
📍 Room: Ensemble C-D | Level 2
🎤 Presentation by Rémi Sabatier at 10:10 AM

A Major Scientific Milestone

This presentation represents the first peer-reviewed scientific outcome from CardiaMetrics to be showcased on an international stage.

Being selected for THT, a best-in-class conference gathering global leaders in cardiovascular innovation, is a strong validation of our technology and scientific approach. It reflects growing recognition from the clinical and research community of our work in reconstructing intracardiac pressures using machine learning.

Advancing Low-Invasive Hemodynamic Monitoring

Our study demonstrates that a low-invasive cutaneous device combined with advanced machine learning algorithms can estimate pulmonary capillary wedge pressure (PCWP), a critical hemodynamic parameter in the management of heart failure patients.

Accurate assessment of intracardiac pressure typically requires invasive procedures or heavily implantable sensors. Our approach aims to provide a scalable, data-driven alternative capable of supporting earlier detection of decompensation and more proactive disease management.

This research represents an important step toward bridging the gap between traditional remote monitoring solutions and low-implantable pressure sensors.

Built on Clinical Research with CHU de Caen

These results stem from the clinical study we initiated in collaboration with CHU de Caen. This early feasibility study laid the foundation for validating our technology.

The data generated through this collaboration enabled the development and validation of our machine learning models for reconstructing intracardiac pressure low-invasively.

Read previous article

Scientific Recognition of Our Machine Learning Approach

The acceptance of our abstract at THT underscores the scientific community’s recognition of our physiology-based machine learning methodology. Reconstructing intracardiac pressure from non-invasive signals represents a significant technological challenge — and a meaningful opportunity to transform heart failure management.

This milestone reflects the dedication of our expanding team, the strength of our clinical partnerships, and the continued trust of our investors and collaborators.

Looking Ahead

Presenting at THT Boston marks the beginning of CardiaMetrics’ international scientific visibility. We look forward to engaging with clinicians, researchers, and industry leaders to further advance innovation in scalable, low-invasive hemodynamic monitoring.

This achievement reinforces our mission: to redefine heart failure care through intelligent, accessible, and clinically validated remote monitoring solutions.

On February 4–5, 2026, Grenoble will become the meeting point for those shaping the technologies of tomorrow.
On this occasion, CardiaMetrics will be attending Tech&Fest, the must-attend tech event of the start of the year, bringing together startups, industry leaders, researchers, investors, and decision-makers around a shared ambition: to build innovation that is useful, responsible, and sovereign.

An Edition Focused on Sovereignty

For its 3rd edition, Tech&Fest has chosen a strong central theme: “Sovereignty.”
Economic, industrial, energy, and digital sovereignty — but also health sovereignty.

A topic that strongly resonates with CardiaMetrics’ mission:
👉 to contribute to a more effective and sustainable management of heart failure, through innovative medical technologies developed in Europe and designed to address real healthcare system challenges.

Why Tech&Fest Is a Key Event for CardiaMetrics

Participating in Tech&Fest means much more than showcasing innovation. It means engaging with a committed, multidisciplinary ecosystem.

Over two days, the program includes:

• 💡 More than 250 high-level speakers sharing their insights on strategic topics such as AI, cybersecurity, quantum technologies — and of course medtech, at the heart of healthcare transformation.

• 🔎 Four immersive thematic areas and over 350 exhibitors — startups, SMEs, and large corporations — ready to showcase the innovations shaping our future.

• 🌍 A Decarbonation Village, highlighting the need for technological progress aligned with environmental responsibility.

• 🤝 More than 20,000 B2B participants: executives, researchers, entrepreneurs, investors — with many dedicated networking opportunities.

Advancing Healthcare, Together

At CardiaMetrics, we firmly believe that major healthcare breakthroughs emerge from collaboration — between engineering, clinical practice, research, and industry.
Tech&Fest provides the ideal environment to challenge ideas, share experiences, and build synergies around a common goal: putting technology at the service of patients and healthcare professionals.

We look forward to meeting those who, like us, believe in rigorous, ethical innovation focused on real-world impact.

📍 Join us on February 4–5, 2026, in Grenoble
🔗 https://www.tech-fest.fr/

Will you be there?

As 2025 draws to a close, we are heading to the Heart Failure Congress, which will be our last scientific event of the year. More than just another conference on the calendar, this moment represents a meaningful milestone for the CardiaMetrics team: a final opportunity to share what we have accomplished this year, to connect with the community, and to gather inspiration that will shape our vision for 2026.

A Year of Progress and Learning

Throughout 2025, CardiaMetrics has remained deeply engaged in advancing data-driven insights in cardiovascular care. From refining our technologies to strengthening collaborations with clinicians and researchers, this year has been defined by a shared goal: better understanding the heart through smarter data.

Attending scientific congresses has been a key part of this journey. Each event has allowed us to test ideas, listen to real-world clinical needs, and align our innovations with the realities of patient care. The Heart Failure Congress feels like the natural place to pause, reflect, and take stock of how far we’ve come.

Looking Ahead to 2026

As our final event of the year, the Heart Failure Congress marks a transition point. It’s a moment to close one chapter and begin shaping the next. The discussions, ideas, and perspectives we gather here will directly inform our roadmap for 2026, ensuring that our work continues to align with the most pressing challenges in heart failure care.

We are excited to engage with fellow researchers, clinicians, and innovators, and to leave this congress not only with new knowledge, but with renewed energy and clarity for the year ahead.

If you’re attending the Heart Failure Congress, we’d be delighted to connect and exchange perspectives. Let’s close out 2025 together—and start building what comes next.